Bailong Chuangyuan(SH:605016) Xin Lang Cai Jing·2025-11-27 07:43Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth in its health sweetener products, particularly allulose, which is beneficial for obesity and diabetes patients. The company is also benefiting from its stake in a rural commercial bank and the depreciation of the RMB, while being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners, with revenue contributions of 54.15% from dietary fiber, 28.00% from prebiotics, and 13.57% from health sweeteners [8]. - As of October 31, the company had 13,400 shareholders, with an average of 31,274 circulating shares per person, reflecting a 3.62% decrease [8]. - The company reported a revenue of 969 million yuan for the period from January to September 2025, representing an 18.10% year-on-year growth, and a net profit of 265 million yuan, which is a 44.93% increase year-on-year [8]. Group 2: Financial Performance - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. - The average trading cost of the company's shares is 20.58 yuan, with the current stock price near a support level of 20.53 yuan [7]. - The company’s market capitalization is 8.677 billion yuan, with a trading volume of 40.56 million yuan and a turnover rate of 0.47% on November 27 [1]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitiveness and stability within the industry [4]. - The company’s overseas revenue accounts for 60.62% of its total revenue, benefiting from the depreciation of the RMB [4].